Mariangela Lombardi1, Teresa Cascone2, Elena Guenzi2, Alessandro Stecco2, Francesco Buemi2, Marco Krengli3, Alessandro Carriero2. 1. Department of Radiology, Maggiore della Carità University Hospital, University of Eastern Piedmont, Corso Mazzini 18, 28100, Novara, Italy. mariangela.lombardi@gmail.com. 2. Department of Radiology, Maggiore della Carità University Hospital, University of Eastern Piedmont, Corso Mazzini 18, 28100, Novara, Italy. 3. Department of Radiotherapy, "Maggiore della Carità" University Hospital, University of Eastern Piedmont, Corso Mazzini 18, 28100, Novara, Italy.
Abstract
OBJECTIVE: This study aimed at evaluating the role of "baseline" apparent diffusion coefficent (ADC), in patients affected by head and neck cancer treated with radio-chemotherapy, as a potential marker of response to therapy. METHODS: Fifty-seven patients underwent pretreatment ADC maps. Minimum, maximum, and medium ADC were computed. Age, dose, treatment time, and ADC values were compared between the two groups (Group 1: local control; Group 2: relapse/persistence of disease) using the Student t test two-tailed unpaired. Two-tailed Fischer exact test was used to compare T stage, N stage, grading and type of treatment between two groups. We have analyzed the receiver operating characteristic (ROC) of statistically significant variables. RESULTS: In patients with local control, values of pre-treatment medium and minimum ADC were lower than ADC values of patients with persistent or recurrent disease, with values, respectively, of 0.83 ± 0.02 × 10-3 mm2/s and 0.59 ± 0.02 × 10-3 mm2/s (vs 0.94 ± 0.05 × 10-3 mm2/s and 0.70 ± 0.05 × 10-3 mm2/s). ROC curve analysis displayed statistical significance as regarding the medium ADC value, showing a sensitivity of 50% and a specificity of 84.8%. ROC analysis of the values minimum ADC showed a sensitivity of 42.9% and specificity of 87.9%. CONCLUSION: The value of the ADC pre-treatment of patients with local control of the disease is lower than that of patients with persistent disease or recurrence.
OBJECTIVE: This study aimed at evaluating the role of "baseline" apparent diffusion coefficent (ADC), in patients affected by head and neck cancer treated with radio-chemotherapy, as a potential marker of response to therapy. METHODS: Fifty-seven patients underwent pretreatment ADC maps. Minimum, maximum, and medium ADC were computed. Age, dose, treatment time, and ADC values were compared between the two groups (Group 1: local control; Group 2: relapse/persistence of disease) using the Student t test two-tailed unpaired. Two-tailed Fischer exact test was used to compare T stage, N stage, grading and type of treatment between two groups. We have analyzed the receiver operating characteristic (ROC) of statistically significant variables. RESULTS: In patients with local control, values of pre-treatment medium and minimum ADC were lower than ADC values of patients with persistent or recurrent disease, with values, respectively, of 0.83 ± 0.02 × 10-3 mm2/s and 0.59 ± 0.02 × 10-3 mm2/s (vs 0.94 ± 0.05 × 10-3 mm2/s and 0.70 ± 0.05 × 10-3 mm2/s). ROC curve analysis displayed statistical significance as regarding the medium ADC value, showing a sensitivity of 50% and a specificity of 84.8%. ROC analysis of the values minimum ADC showed a sensitivity of 42.9% and specificity of 87.9%. CONCLUSION: The value of the ADC pre-treatment of patients with local control of the disease is lower than that of patients with persistent disease or recurrence.
Entities:
Keywords:
Baseline apparent diffusion coefficent (ADC); Diffusion; Early response; Head and neck cancer; Radio-chemotherapy
Authors: Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Vincent Vandecaveye; Piet Dirix; Frederik De Keyzer; Katya Op de Beeck; Vincent Vander Poorten; Esther Hauben; Maarten Lambrecht; Sandra Nuyts; Robert Hermans Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-20 Impact factor: 7.038
Authors: R K Gupta; T F Cloughesy; U Sinha; J Garakian; J Lazareff; G Rubino; L Rubino; D P Becker; H V Vinters; J R Alger Journal: J Neurooncol Date: 2000-12 Impact factor: 4.130
Authors: Sungheon Kim; Laurie Loevner; Harry Quon; Eric Sherman; Gregory Weinstein; Alex Kilger; Harish Poptani Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: M Ravanelli; A Grammatica; M Maddalo; M Ramanzin; G M Agazzi; E Tononcelli; S Battocchio; P Bossi; M Vezzoli; R Maroldi; D Farina Journal: AJNR Am J Neuroradiol Date: 2020-07-30 Impact factor: 3.825
Authors: Valerio Nardone; Maria Grazia Calvanese; Ida D'Onofrio; Mario Di Stasio; Claudio Vitale; Antonia Silvestri; Bruno Daniele; Pierpaolo Correale; Paolo Fierro; Giuseppe Tortoriello; Alfonso Reginelli; Salvatore Cappabianca; Cesare Guida Journal: Rep Pract Oncol Radiother Date: 2020-04-12
Authors: Steve Connor; Cherry Sit; Mustafa Anjari; Teresa Szyszko; Joel Dunn; Irumee Pai; Gary Cook; Vicky Goh Journal: Cancer Rep (Hoboken) Date: 2021-05-07